Charles River Laboratories International (CRL) said Tuesday it has entered a partnership with Central European Biotech Incubator and Accelerator, or CEBINA, to support CEBINA's DanubeNeuro program, aimed at accelerating innovative academic research in neurodegenerative diseases.
Financial details of the partnership weren't disclosed.
The partnership combines Charles River's central nervous system drug development expertise with CEBINA's focus on advancing novel drugs, diagnostics, and biomarkers for conditions like Alzheimer's and Parkinson's, Charles River Laboratories said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments